Parabilis Medicines, Inc. 8-K

What Happened Parabilis Medicines, Inc. announced that on June 9, 2026 it entered a Stock Purchase Agreement with Regeneron Pharmaceuticals, Inc. for the private placement purchase of 4,166,666 shares of voting common stock. The private placement closed on June 11, 2026, concurrent with Parabilis’ IPO, where the IPO price was $20.00 per share and Regeneron paid 90% of that price (i.e., $18.00 per share).

Key Details

• Shares sold: 4,166,666 shares of voting common stock (par value $0.0001).
• Price: 90% of the IPO price ($20.00), equal to $18.00 per share.
• Proceeds: approximately $75.0 million (4,166,666 × $18.00 = $74,999,988).
• Agreement terms: Regeneron is entitled to piggyback registration rights; the Purchase Agreement contains customary representations and warranties.
• Corporate charter/bylaws: effective with the IPO, the company filed an amended and restated certificate of incorporation authorizing 800,000,000 shares of common stock (600,000,000 voting; 200,000,000 non-voting) and 10,000,000 undesignated preferred shares, and eliminated references to prior preferred series. The amended and restated bylaws establish procedures for shareholder actions, advance notice for proposals/nominations, and conform to the amended charter.

Why It Matters This 8-K reports a significant investor placement tied to Parabilis’ IPO that brought a strategic buyer (Regeneron) into the register with roughly $75 million of purchase consideration. The charter and bylaw amendments materially change the company’s authorized capital structure (large pools of voting and non‑voting common shares and undesignated preferred stock) and set formal shareholder notice/nominations procedures — all of which affect potential dilution, future financings, and governance. Investors should note the piggyback registration rights that may enable Regeneron to sell shares alongside future company registrations.